Derazantinib Showed Clinical Benefit as a Second-Line Treatment for Patients Wit
- This topic has 0 replies, 1 voice, and was last updated 2 years, 2 months ago by
.
Viewing 1 post (of 1 total)
-
Posts
-
Derazantinib Showed Clinical Benefit as a Second-Line Treatment for Patients With Intrahepatic Cholangiocarcinoma and EGFR2 Aberrations
Thanks to HMP Global Learning Network for this piece.
Gavin
Viewing 1 post (of 1 total)
- The forum ‘Chemotherapy & More’ is closed to new topics and replies.